StonvexLoading…
StonvexStonvexStonvexCore line items from EPSN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $25.60M | $51.59M | $36.77M | $27.79M |
Operating Income | $10.81M | $-10.52M | $8.60M | $8.00M |
Net Income | $729.42K | $-5.80M | $1.07M | $1.55M |
EPS (Diluted) | $0.02 | $-0.25 | $0.30 | $0.25 |
Total Assets | $226.42M | $228.24M | $126.29M | $123.61M |
Total Liabilities | $102.30M | $103.51M | $26.07M | $23.42M |
Cash & Equivalents | $7.91M | $8.96M | $12.77M | $9.91M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 30.24M | 30.24M | 22.06M | 22.02M |